Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Clinical Outcomes of PRX S With Standardized Home Care in Mild-to-Moderate Facial Acne. (PRXS-SINGLE)

10 de noviembre de 2026 actualizado por: Medical University of Silesia

Changes in Inflammatory Lesion Count, Tolerability, and Clinical and Instrumental Skin Parameters Following Five PRX S Sessions Combined With Standardized Home Care in Adults With Mild-to-Moderate Facial Acne: A Prospective, Single-Arm, Open-Label Clinical Study.

This study aims to assess changes in facial acne lesions and skin condition following a series of five PRX S treatments combined with standardized home skin care in adults with mild-to-moderate acne.

The study will include 30 adults aged 18-60 years with mild-to-moderate facial acne. All participants will receive five PRX S treatments at two-week intervals and use the same home-care products, including a nourishing cream and an active Balancing Cream.

The main objective is to determine how the number of inflammatory acne lesions (papules and pustules) changes from the beginning of the study to two weeks after the fifth treatment. The study will also assess other acne lesions, overall acne severity, skin oiliness, hydration, elasticity, skin surface characteristics, and skin thickness using clinical examinations and specialized instruments. Skin tolerability and any adverse events will also be monitored.

Participants will undergo assessments before treatment, after three completed treatments, two weeks after the fifth treatment, and approximately two months later.

All participants will receive the same treatment regimen. There will be no placebo or untreated comparison group. Therefore, the study will describe changes observed during the combined treatment program but will not determine the separate effects of PRX S or establish its superiority over other treatments.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Descripción detallada

This study aims to assess changes in facial acne lesions and skin condition following a series of five PRX S treatments combined with standardized home skin care in adults with mild-to-moderate acne.

The study will include 30 adults aged 18-60 years with mild-to-moderate facial acne. All participants will receive five PRX S treatments at two-week intervals and use the same home-care products, including a nourishing cream and an active Balancing Cream.

The main objective is to determine how the number of inflammatory acne lesions (papules and pustules) changes from the beginning of the study to two weeks after the fifth treatment. The study will also assess other acne lesions, overall acne severity, skin oiliness, hydration, elasticity, skin surface characteristics, and skin thickness using clinical examinations and specialized instruments. Skin tolerability and any adverse events will also be monitored.

Participants will undergo assessments before treatment, after three completed treatments, two weeks after the fifth treatment, and approximately two months later.

All participants will receive the same treatment regimen. There will be no placebo or untreated comparison group. Therefore, the study will describe changes observed during the combined treatment program but will not determine the separate effects of PRX S or establish its superiority over other treatments.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

30

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Anna Deda, PhD
  • Número de teléfono: +48 500 233 457
  • Correo electrónico: adeda@sum.edu.pl

Ubicaciones de estudio

      • Mysłowice, Polonia, 41-400
        • AJ Med
        • Contacto:
          • Anna Deda
          • Número de teléfono: +48 500 233 457
          • Correo electrónico: adeda@sum.edu.pl
      • Sosnowiec, Polonia, 41-208
        • Department of Practical Cosmetology and Skin Diagnostics
        • Contacto:
          • Anna Deda, PhD
          • Número de teléfono: +48 500 233 457
          • Correo electrónico: adeda@sum.edu.pl

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 60 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Adults aged 18-60 years.
  • Mild-to-moderate facial acne vulgaris, defined as Investigator's Global Assessment (IGA) grade 2 or 3, confirmed by a dermatologist at baseline (T0).
  • Presence of at least five inflammatory facial acne lesions (papules and/or pustules) at baseline.
  • Provision of written informed consent to participate in the study and undergo study-related assessments and documentation.
  • No contraindications to the study products and confirmation by a dermatologist that the treatment regimen is clinically appropriate.
  • Ability and willingness to attend scheduled study visits and comply with the standardized home skin-care regimen.
  • No urgent need for alternative acne treatment that is not provided within the study protocol.

Exclusion Criteria:

  • Investigator's Global Assessment (IGA) grade 0, 1, or 4.
  • Severe or nodulocystic acne, deep inflammatory lesions, or rapidly progressive acne scarring requiring alternative medical management.
  • Pregnancy or breastfeeding.
  • Known hypersensitivity to any component of the study products.
  • Active herpes simplex infection, other skin infections, wounds, erosions, or burns in the treatment area.
  • Active atopic dermatitis, seborrheic dermatitis, or other skin conditions that may interfere with study assessments.
  • Skin malignancy or suspicious lesions in the treatment area.
  • Medical conditions or concurrent therapies that may significantly increase treatment-related risks or interfere with the interpretation of study outcomes.
  • Use of topical retinoids within 30 days before baseline (T0).
  • Completion of anti-acne antibiotic therapy less than 3 months before baseline (T0).
  • Completion of isotretinoin therapy less than 6 months before baseline (T0).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: PRX S Treatment Combined With Standardized Home Care

Participants will receive five professional PRX S facial treatments at approximately 14-day intervals (days 0, 14, 28, 42, and 56), combined with standardized home skin care consisting of WIQO Nourishing Cream for Normal and Combination Skin applied in the morning and WIQO Balancing Cream applied in the evening. Home care will continue throughout the study, including the follow-up period. Clinical and instrumental assessments will be performed at baseline (T0), after three completed treatments (T1), two weeks after the fifth treatment (T2), and two calendar months after T2 (T3). All participants will receive the same combined regimen, with no placebo or comparator group.

PRX S is a two-phase topical preparation activated immediately before professional application according to the manufacturer's instructions for use. Participants will undergo five facial treatment sessions at approximately 14-day intervals (days 0, 14, 28, 42, and 56). The procedure will be performed using a standardized protocol appropriate for mild-to-moderate facial acne. The application technique, treatment quantity, and number of layers will follow the approved standard operating procedure and current manufacturer's instructions.

All participants will follow a standardized home skin-care regimen using WIQO Nourishing Cream for Normal and Combination Skin and WIQO Balancing Cream. The nourishing cream will be used in the morning and the Balancing Cream in the evening according to the approved study instructions. Home care will continue throughout the treatment and follow-up periods. The regimen will be identical for all participants.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change From Baseline in Inflammatory Facial Acne Lesion Count at Day 70
Periodo de tiempo: Baseline (Day 0) and Day 70 (14 days after the fifth treatment)

The outcome is the within-participant change in the total number of inflammatory facial acne lesions (papules and pustules) between baseline (T0) and T2. Lesions will be counted by a trained dermatologist using a standardized facial lesion-counting procedure. The change will be calculated as the T2 lesion count minus the baseline lesion count. A negative value indicates a reduction in inflammatory lesions.

Baseline (Day 0) and Day 70 (14 days after the fifth treatment)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change From Baseline in Inflammatory Facial Acne Lesion Count at Day 42
Periodo de tiempo: Baseline (Day 0) and Day 42 (after three completed treatments, before the fourth treatment).

Change in the total number of facial inflammatory acne lesions (papules and pustules), counted by a trained dermatologist. The change is calculated as the Day 42 count minus the baseline count. Negative values indicate improvement.

Baseline (Day 0) and Day 42 (after three completed treatments, before the fourth treatment).
Change From Baseline in Inflammatory Facial Acne Lesion Count at Follow-up
Periodo de tiempo: Baseline (Day 0) and T3 (two calendar months after Day 70).

Change in the total number of facial inflammatory acne lesions (papules and pustules) between baseline and T3, assessed by a trained dermatologist using standardized lesion counting. Negative values indicate a reduction in inflammatory lesions.

Baseline (Day 0) and T3 (two calendar months after Day 70).
Change From Baseline in Facial Comedone Count
Periodo de tiempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Change in the total number of non-inflammatory facial acne lesions, including open and closed comedones, assessed by a trained dermatologist using standardized lesion counting. The change at each post-baseline visit is calculated as the visit count minus the baseline count. Negative values indicate fewer comedones.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
Percentage Reduction From Baseline in Inflammatory Facial Acne Lesion Count
Periodo de tiempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Percentage reduction in the total number of facial inflammatory acne lesions (papules and pustules), calculated as 100 × (baseline lesion count - post-baseline lesion count) / baseline lesion count. Positive values indicate a reduction in inflammatory lesions. Participants are required to have at least five inflammatory lesions at baseline.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
Change in Investigator's Global Assessment of Acne Severity
Periodo de tiempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Acne severity will be assessed by a dermatologist using the static Investigator's Global Assessment (IGA) scale ranging from 0 (clear) to 4 (severe). The distribution of IGA grades and changes in grades from baseline will be reported at each assessment visit. Lower grades indicate less severe acne.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
Percentage of Participants Achieving an Investigator's Global Assessment Grade of 0 or 1
Periodo de tiempo: Day 42, Day 70, and T3 (two calendar months after Day 70).

Percentage of evaluable participants achieving an Investigator's Global Assessment (IGA) grade of 0 (clear) or 1 (almost clear) at each post-baseline assessment. IGA is a five-category ordinal scale ranging from 0 (clear) to 4 (severe).

Day 42, Day 70, and T3 (two calendar months after Day 70).
Percentage of Participants Achieving Investigator's Global Assessment Success
Periodo de tiempo: Day 42, Day 70, and T3 (two calendar months after Day 70).

IGA success is defined as achieving an Investigator's Global Assessment grade of 0 (clear) or 1 (almost clear), together with an improvement of at least two grades from baseline. Participants with baseline IGA 2 must achieve grade 0, while participants with baseline IGA 3 may achieve grade 0 or 1.

Day 42, Day 70, and T3 (two calendar months after Day 70).
Change From Baseline in Facial Skin Sebum Level Measured by Sebumetry
Periodo de tiempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Facial skin surface sebum will be measured using a sebumeter under standardized measurement conditions. Results will be expressed in micrograms per square centimeter (µg/cm²). Changes from baseline will be calculated at each post-baseline assessment.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
Change From Baseline in Stratum Corneum Hydration Measured by Corneometry
Periodo de tiempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Skin hydration will be assessed using corneometry under standardized measurement conditions. Measurements reflect hydration of the stratum corneum and are expressed in instrument-specific arbitrary units. Changes from baseline will be calculated at each post-baseline assessment.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
Change From Baseline in Skin Elasticity (Cutometer R2 Parameter)
Periodo de tiempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Skin biomechanical properties will be assessed using a Cutometer. The R2 parameter, representing gross skin elasticity, will be recorded as a dimensionless ratio. Changes from baseline will be calculated at each post-baseline assessment.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
Change From Baseline in Dermal Thickness Measured by Skin Ultrasonography
Periodo de tiempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Dermal thickness will be measured using skin ultrasonography at standardized anatomical measurement sites. Results will be expressed in millimeters (mm). Changes from baseline will be calculated at each post-baseline assessment.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
Change From Baseline in Dermal Echogenicity Measured by Skin Ultrasonography
Periodo de tiempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Dermal echogenicity will be assessed using skin ultrasonography under standardized acquisition conditions. Results will be expressed in instrument-specific arbitrary units. Changes from baseline will be calculated at each post-baseline assessment.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).
Change From Baseline in Facial Skin Surface Parameters Assessed by Antera 3D
Periodo de tiempo: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Changes in facial skin surface characteristics, including pore-related parameters, skin texture, and surface roughness, will be assessed using the Antera 3D imaging system. Measurements will be performed at standardized anatomical sites and compared with baseline values.

Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Colaboradores

Investigadores

  • Investigador principal: Anna Deda, PhD, Medical University of Silesia in Katowice, Poland

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

30 de marzo de 2027

Finalización del estudio (Estimado)

31 de mayo de 2027

Fechas de registro del estudio

Enviado por primera vez

10 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

De-identified individual participant data underlying the reported study results may be made available to qualified researchers upon reasonable request, subject to participant consent, applicable data protection requirements, and authorization by the study sponsor. Data sharing will be considered on a case-by-case basis.

Marco de tiempo para compartir IPD

De-identified individual participant data may be made available upon reasonable request following publication of the main study results, subject to participant consent, applicable data protection requirements, and sponsor authorization. The duration of availability will be determined in accordance with the sponsor's data retention and sharing policies.

Criterios de acceso compartido de IPD

De-identified individual participant data underlying the published study results may be made available to qualified researchers upon reasonable request. Requests will be reviewed on a case-by-case basis and will be subject to participant consent, applicable data protection requirements, and authorization by the study sponsor. Access will be limited to data approved for sharing. Participant-identifiable information and identifiable facial photographs will not be shared without the appropriate consent and legal basis.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir